Funding for this research was provided by:
National Life Safety Emergency Response Research Program of the National Research Foundation of Korea (2020M3E9A1085862)
Received: 24 November 2020
Accepted: 26 October 2021
First Online: 23 November 2021
: The research shall be carried out in compliance with the approved research plan and the researcher’s compliance, and all data of the subjects shall be anonymized, kept strictly confidential, passwords shall be set and kept in a separate file, and personal information shall not be verified through the research data. The investigation will proceed after the confirmed patients of COVID-19 infection, who are admitted to hospitals, get enough explanation of the investigation and submit their written agreement. The subjects will receive a sufficient description of the disease, drug, and the investigation before signing the consent document, by considering the situation, where the subject (including the legal representative) is isolated according to the KFDA’s [notice for the clinical trials of COVID-19]. If consent/instruction (signed original) provided to the subject is to be destroyed in the process of consent to participate in the research, the original photo of consent signed by the subject and the researcher will be replaced, and the instructions will be provided to the subject (legal representative) when the quarantine is released.
: Not applicable
: The authors declare that they have no competing interests.